Login to Your Account

CFDA continues reforms, cracks down on dubious drug approval applications

By Pearl Liu
Staff Writer

Tuesday, September 20, 2016

HONG KONG – China's pharmaceutical industry is undergoing a painful reform as regulations tighten, in particular a recent push by the CFDA to clamp down on untrustworthy clinical trial data.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription